Global Pharma
Timeline
11 events since 2021Filings
Financial
Establishments
Address
202220242026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBmicro format · 31 days late
Registered office moved from Waasmunster to Sint-NiklaasNew registered office: Dubbelhofstraat 10 bus A, 9111 SINT-NIKLAAS · Previous registered office: Schrijbergstraat 208, 9250 WAASMUNSTER2 points ▸
- Registered-office move, Dubbelhofstraat 10 bus A, 9111 SINT-NIKLAAS
- Power of attorney, DKF Fiduciaire nv
2025
Equity above €100,000 equity €121,563 ▲26% With a profit in every financial year since 2021, equity grows to €121,563.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0769932847
Annual accounts 2024 filed PDFmicro format · 54 days late
2024
Annual accounts 2023 filed PDFmicro format · 48 days late
2023
Annual accounts 2022 filed PDFmicro format · 55 days late
2022
Weakest financial year net €7,454 ▼79.4% The net result drops to €7,454, the lowest from 2021 to 2025. It recovers the following year.
Annual accounts 2021 filed PDFmicro format · 29 days late
2021
IncorporationDemerger: PATRIMANNE splits off to GLOBAL PHARMA · Appointment: OLERNI (director) · Permanent representative: VAN HERREWEGE Laurence Martine Clara Maria · published on 30-06-20214 points ▸
- General meeting, 14-06-2021
- Registered office clause, Schrijbergstraat 208, 9250 Waasmunster
- Director appointment, OLERNI
- Permanent representative, VAN HERREWEGE Laurence Martine Clara Maria
- The deed holds 8 more points.
First establishment Schrijbergstraat 208, Waasmunster
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Global Pharma was incorporated on 22 June 2021 as a private limited company.1 The registered office was moved to Sint-Niklaas in 2026.2 Since 2021, OLERNI has served as director.3 Total assets rose from €242,306 in 2021 to €403,675 in 2025 and headcount from 2 full-time equivalents in 2023 to 2 in 2025.4